OncoMatch/Clinical Trials/NCT05800587
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Is NCT05800587 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for lung cancer.
Treatment: Carboplatin · Pemetrexed · Paclitaxel · Nab paclitaxel · Docetaxel · Gemcitabine · Etoposide · Irinotecan · Topotecan · Lurbinectedin — This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Disease stage
Required: Stage IV, III (AJCC version 8)
stage IV (AJCC version 8) lung cancer (small cell or non-small cell). Patients with stage III disease who are not felt to be candidates for definitive therapy are also eligible.
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: targeted therapy (TKI, sotorasib)
Exception: if not combined with a cytotoxic agent
Patients receiving only a targeted agent (e.g. TKI, sotorasib etc.) or immunotherapy without a cytotoxic agent
Cannot have received: immunotherapy
Exception: if not combined with a cytotoxic agent
Patients receiving only a targeted agent (e.g. TKI, sotorasib etc.) or immunotherapy without a cytotoxic agent
Cannot have received: investigational agent
Patients currently receiving investigational agents for cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fox Chase Cancer Center · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify